Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - SAVA

Core Viewpoint - The Gross Law Firm is notifying shareholders of Cassava Sciences, Inc. regarding a class action lawsuit related to the company's drug candidate simufilam, which failed to meet clinical trial endpoints, leading to a significant stock price decline [1][2]. Group 1: Allegations and Impact - Shareholders who purchased shares of Cassava Sciences (SAVA) between February 7, 2024, and November 24, 2024, are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment [1]. - The complaint alleges that the defendants provided misleading information about simufilam's efficacy in treating Alzheimer's Disease, expressing confidence that was not substantiated by trial results [1]. - Following the release of disappointing Phase 3 study results on November 25, 2024, Cassava's stock plummeted from $26.48 to$4.30 per share, a decline of approximately 83.76% in one day [1]. Group 2: Next Steps for Shareholders - The deadline for shareholders to register for the class action is February 10, 2025, and they will be enrolled in a portfolio monitoring system for updates on the case [2]. - Participation in the case does not incur any costs or obligations for shareholders [2]. Group 3: Firm's Commitment - The Gross Law Firm is recognized for its commitment to protecting investors' rights against deceit and fraud, aiming to hold companies accountable for misleading practices that inflate stock prices [3].